Triethylenetetramine (TETA), a Cu(II)-selective chelator, is commonly used for the treatment of Wilson's disease. Recently, it has been demonstrated that TETA can be used in the treatment of cancer because it possesses telomerase inhibiting and antiangiogenesis properties.
Introduction
Triethylenetetramine (TETA), a Cu II -selective chelator and an orphan drug, is commonly used for the treatment of Wilson's disease (1). Recently, its potential uses in cancer chemotherapy and other diseases are under investigation.
Wilson's disease is an autosomal recessive genetic disorder, manifested by copper accumulation in tissues of patients (2) . Illness presents as neurological or psychiatric symptoms and liver disease, resulting in death of patients and was considered an incurable disease until the 1950s. Treatments of this disease using orphan drugs were developed in the 1950s by John Walshe (3) . Currently, common treatments for Wilson's disease either reduce copper absorption by using zinc acetate or remove the excess copper from the body using chelators such as penicillamine and TETA (4) .
Recently, it was demonstrated that TETA could ameliorate left ventricular hypertrophy in humans and rats with diabetes (5-7). It has also been suggested that TETA can be used in the treatment of cancer because it is a telomerase inhibitor (8) , and has antiangiogenesis properties (9-11) based on pre-clinical investigations. In addition, a recent report showed that TETA treatment could overcome cisplatin resistance in human ovarian cancer cell culture via inhibition of superoxide dismutase 1 / Cu/Zn superoxide dismutase (12) . Another recent report showed that TETA could induce apoptosis in murine fibrosarcoma cells by activation of the p38 MARK pathway (13) . However, no clinical trial or trial plan using TETA to treat cancer has been reported in the literature. Since TETA is an orphan drug and has been used in clinic for decades, it can be tested readily in clinical cancer chemotherapy. However, in order to take the advantage of the possible benefits of TETA in clinical cancer treatment, a thorough understanding of TETA pharmacology is crucial. gaps in TETA pharmacology that need to be addressed, despite its decades of clinical use in patients with Wilson's disease.
Chemistry and Detection
TETA is a structure analog of linear polyamine compounds spermidine and spermine (see Figure 1) . It was first made in Berlin, Germany in 1861 and was made as a dihydrochloride salt in 1896 (15) . Its chelation activity was studied at Cambridge University in 1925 (15) . Cu II prefers nitrogen to oxygen as a ligand, and because TETA has four nitrogen groups, it fits the square-planar geometry in which Cu II is most stable (Figure 1 ). (23) addressed those concerns. An HPLC-conductivity detection method has also been developed (26), but its detection limit is relatively high, rendering poor sensitivity to the method.
Recently, a non-derivatized method using liquid chromatography-mass spectrometry (LC-MS) has been developed to detect TETA and its two major metabolites simultaneously in aqueous solutions (27), providing more sensitive detection and analytical power. With the availability of the LC-MS/MS technology, method with higher sensitivity and accuracy could be developed to study TETA and its metabolites in human samples, which will certainly facilitate future pharmacological studies of TETA.
Pharmacokinetics

Summary of Pharmacokinetic Parameters in Pre-clinical and Clinical Situations
Pharmacokinetic parameters in pre-clinical studies are summarized in The bioavailability range of oral trientine in fasted rats was first reported at 6-18% (28). Later reports provided similar results. One study reported a bioavailability of 2.31% in non-fasted rats and 6.56% in fasted rats (30). A second report showed bioavailability in three fasted rats at 5.6%, 5.7% and 16.4%, respectively (20) . A third report provided a bioavailability of 14.0% in non-fasted rats and 25.5% in fasted rats (32). A fourth report determined that the bioavailability in fasted rats was 13.78% (31). Overall, the bioavailability of oral TETA administration is relatively low in rats and food intake seems to reduce it further.
Absorption -Humans
In humans, the absorption rate in the gut after oral trientine administration is also relatively slow. The T max values from various studies occur between 0.8-4 h ( Table 2) , indicating overall slow absorption. There seems to be a large variance of C max (0.4 -20 mg/L) among different individuals with Wilson's disease who had been dosed with 600 mg trientine in one early study (20) . However, the C max variance seems to be less profound in healthy volunteers on the same dose, i.e. 0.80 ± 0.33 mg/L (mean ± SD) in one recent study (40), and 0.69 ± 0.41 mg/L in another recent report (39) . Food intake inhibits absorption, as
shown by reduced C max and decreased AUC in one healthy volunteer (22) . The parameter of bioavailability has not been measured in humans.
Distribution -Animals
TETA is widely distributed into various tissues in rats, either in the form of unchanged parent compound or biotransformed metabolite(s). The earliest study performed by Gibbs and Walshe using 14 C radio-labeled TETA·4HCl showed that liver, kidney and MCT-10-0523
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Copyright © 2010 American Association for Cancer Research muscle had higher TETA concentrations than that quantified in plasma (28). A later study using 14 C radiolabeled trientine showed that TETA could be found in most rat tissues, including cerebrum, cerebellum, hypophysis, eyeball, harderian gland, thyroid, submaxillary gland, lymphatic gland, thymus, heart, lung, liver, kidney, adrenal, spleen, pancreas, fat, brown fat, muscle, skin, bone marrow, testis, epididymis, prostate gland, stomach, small intestine and large intestine (34) . However, concentrations in liver and kidney appeared to be much higher than that in plasma, and plasma concentrations were higher than that observed for other tissues. Apart from liver and kidney, other tissues did not accumulate significant amounts of TETA after oral administration. In the analyses, it was observed that both the parent compound and metabolite(s) exist in all tissues (33). A later report confirmed such findings, showing that concentration ratios of liver/plasma and kidney/plasma were greater than 1, while brain, lung, spleen and white fat have ratios lower than 1 (31).
It is proposed that TETA shares a common transport mechanism with polyamines in intestinal uptake. It is likely that TETA is also transported across biological membrane into mammalian cells by the same transporter for polyamines. The transporter of polyamines has been identified as glypican-1 (44). Inside cells, polyamines are further transported into mitochondria, where polyamine concentrations can reach millimolar level, electrophoretically by a specific polyamine uniporter (45) . It is therefore not surprising that TETA is widely distributed in the body and can be accumulated in the tissues.
Distribution -Humans
There is no existing data for tissue distribution in humans. Since the bioavailability has not been established in humans, the volume of distribution cannot be calculated from previous published studies. However, a recent study reported that the central and peripheral
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Metabolism -Animals
TETA is extensively metabolized in rats. In vitro experiments have shown that about 50% of TETA was eliminated from the S9 liver fraction system after 2 hr of incubation (29).
One in vivo study in rats showed that after oral administration of trientine, only 3.1% of the dose was found in the 24-hr urine collection as the unchanged parent compound, while metabolites accounted for 32.6% of the oral dose (30). Another in vivo study reported that 2.6% of the dose was recovered from 24-h urine collection as the unchanged parent compound, and 11% metabolites (33). The existence of acetylated metabolites in rats was first proposed then establised by Gibbs and Walshe (28). To date, two acetylated metabolites, N 1 -acetyltriethylenetetramine (MAT) (36, 37) and N 1 ,N 10 -diacetyltriethylenetetramine (DAT) (27, 38), have been identified. TETA metabolite levels in rat tissues have been investigated in two studies. In one study, after oral administration of trientine, the plasma AUC 0-6hr of the metabolite MAT has been reported to be higher than that of unchanged TETA in rats (31).
The same report and another early report (33) both showed that MAT existed in rat tissues at similar levels observed for the unchanged parent compound.
Metabolism -Humans
TETA is extensively metabolized in humans, as a number of metabolites have been found in urine other than the unchanged parent compound. Two major TETA metabolites have been identified from human urine, both of which are acetylation products of TETA. 
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Copyright © 2010 American Association for Cancer Research (unpublished data). Given the fact that TETA is a structural analog of spermidine and spermine, it is not surprising that SSAT is the enzyme that metabolizes TETA in humans.
SSAT may also be responsible for the metabolism of many other polyamine analogs, such as diethylspermine and diethylnorspermine, which are currently in clinical trials for the treatment of cancer (47) .
Excretion/Elimination -Animals
Most of the absorbed TETA is excreted via urine as bile and lung excretions appear to be minimal in animal studies. One study found that after oral trientine administration to rats, 0.69% of the dose was found in expired air and 0.86% of the dose was excreted via bile (34) .
The urinary excreted TETA is mainly in the form of acetylated metabolites, while the unchanged parent compound represents a smaller percentage of the dose (Table 1 ). The renal clearance of TETA in rat is about 30% higher than creatinine clearance, which indicates TETA is actively excreted from the renal tubule into urine (48). It has been identified that the Na + /spermine antiporter in the rat renal tubular brush-border membrane is responsible for active excretion of spermine, TETA and any other straight-chain polyamine compound with more than 4 amino groups (49) . TETA metabolites MAT and DAT, are also straight-chain structures, and with 4 amino groups, they should be able to be actively excreted in kidney as well. Therefore, it is not surprising that a large amount of metabolites are found in rat urine.
Diseases that compromise kidney function in rats seem to affect urinary excretion of TETA. One early study reported that LEC rats, a rat model of Wilson's disease, had significant lower urinary TETA excretion than that in normal Wistar rats. This was due to the impairment of kidney function in LEC rats (29).
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Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. There was one therapeutic termination for non-compliance of the patient with the drug, and one miscarriage associated with a contraceptive coil. The eight normal infants were reported as progressing satisfactorily, and had been studied for periods varying from three months to nine years. All mothers were also reported as doing well. The normal-for-age ceruloplasmin values found in the cord blood indicates that there was no significant Cu depletion in the fetuses, as a result of trientine treatment. In the first case of the two separated case reports, trientine was only used in the last 1-2 weeks prior to delivery, and delivery of a normal baby at 34 weeks by cesarean section was recorded (69) . In the second case, trientine has been used for eight years prior to conception. Trientine was continued throughout the pregnancy, and a normal child was delivered via cesarean section at 42 weeks (70) . Current usage of trientine during pregnancy for Wilson's disease is only recommended where the potential benefit outweighs the potential risk to the fetus.
Pharmacodynamics
Mechanism of Action in Wilson's Disease
TETA is a Cu II -selective chelator, which aids the systemic elimination of divalent Cu from the human body by forming a stable complex that is readily excreted from the kidney (Figure 1 ) (6, 15, 71) . TETA not only increases urinary Cu excretion, but also decreases intestinal copper absorption by 80% (57). TETA and its metabolite, MAT, are both capable of binding divalent Cu, Fe and Zn. However, the chelating activity of MAT is significantly lower than that of TETA (37) . The urinary levels of copper increase in parallel with the amount of TETA excretion in healthy volunteers (37, 38) , but increase in parallel with the sum of TETA and MAT in diabetic patients (38) . The removal of excessive Cu in Wilson's disease patients is regarded as its mechanism of action for treating this disease.
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Mechanism of Action in Cancer
A few mechanisms have been proposed to be the possible mode of action of TETA on cancer cells. A few reports have shown that TETA could be a telomerase inhibitor (8, (72) (73) (74) .
By inhibiting telomerase, TETA might have the selective inhibitory effect or cytotoxicity on tumor growth, because telomerase is an essential factor in cellular immortalization and tumorigenesis, which is expressed in over 85% of all human cancers. It is suggested that TETA inhibit telomerase because it is a ligand for G-quadruplex, and stabilizes both intraand inter-molecular G-quadruplexes (72, 75) .
Another mechanism of TETA action in cancer is thought to be antiangiogenesis.
Copper plays a key role in angiogenesis (76) . Chelation of copper by TETA suppresses several angiogenic mediators, includingVEGF-1, FGF-1, IL-1, IL-6, IL-8 and NF-κB (9-11, 77-80). As a result, TETA exhibits antiangiogenic effects in tumor cells.
Promotion of apoptosis is another proposed mechanism. One recent report suggested that TETA could induce apoptosis in murine fibrosarcoma cells via the activation of the p38 MAPK pathway (13) . Another report suggested that prolonged copper depletion via TETA chelation might induce expression of antioxidants and trigger apoptosis in neuroblastoma cells (81) .
TETA can also be used to overcome cisplatin resistance in ovarian cancer cells by decreasing the over-expressed Cu/Zn superoxide dismutase (12) . Since it is well established that TETA can decrease the over-expressed Cu/Zn superoxide dismutase in human diseases, combination therapy using cisplatin and TETA could be a possible clinical entry point for TETA chemotherapy in cancer.
on Currently, there is no systemic study to investigate the anti-cancer mechanisms of TETA. In order to better understand TETA's anti-cancer effects, more systemically designed studies are needed to show the hierarchy of TETA action in cancer cells, which will certainly guide or benefit future clinical application.
Mechanism of Action in Other Clinical Applications
Recently, TETA has been used in clinical trials for the treatment of diabetic heart failure. It has been shown that there is a hyperglycemia-driven pathogenic abnormality of copper homeostasis in type 2 diabetic patients (5). TETA treatment reduces left ventricular hypertrophy in patients (7) . It also improves left ventricular function (5, 82) , restores damaged aortic and left ventricular structures (5, 83) , and improves cardiac antioxidant defense (83-85) in rat models of diabetes. However, the exact target(s) and mechanism of actions of TETA in diabetic heart failure are still under investigation.
Apart from diabetic heart failure, TETA is effective in treating other diabetic complications. One report has shown that TETA was effective in diabetic nephropathy in a rat model through normalizing renal fibrosis and pathogenic TGF-β activation (85). Two other reports produced data that demonstrated that TETA suppressed carbonyl stress and reduced inflammation in the lenses of diabetic rats. Hence, TETA could be used to assist the treatment of diabetic retinopathy (86, 87) .
Current Clinical Applications and Therapeutic Implications
TETA is currently used as the second line treatment, in the form of trientine, for
Wilson's disease, mainly for those patients with penicillamine allergy or intolerance (14, 88, 89) . It is more commonly used in children with Wilson's disease (16, 66) . The common 
